Ganciclovir studies leave clinicians confused.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000517:prevention & control*; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000284:Administration, Oral; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000998:Antiviral Agents; D010919:Placebos; D014633:Valine; D000077483:Valacyclovir; D015774:Ganciclovir; D000212:Acyclovir